Paragon Therapeutics Launches First Spinout, Apogee Therapeutics, to Advance Novel Therapies for Inflammatory and Immunological Conditions

(December 07, 2022) | By Paragon Therapeutics.

Apogee emerges with $169 million to expand team and progress lead program APG777 into the clinic

Milestone validates Paragon’s strategy to rapidly deliver best-in-class biologic therapies to patients

WALTHAM, Mass., Dec. 7, 2022 /PRNewswire/ — Paragon Therapeutics, a biotechnology company dedicated to discovering and developing best-in-class biologics for a range of diseases with high unmet need, today announced the launch of Apogee Therapeutics, LLC, its first spinout. Apogee is advancing a pipeline of product candidates discovered and developed at Paragon that have potential to reach millions of people living with inflammatory and immunological disorders.

Building on validated protein engineering technologies, Paragon leverages cutting-edge science and technology to rapidly identify and propel biologics from ideation to the clinic. The company’s process combines high-throughput screening systems and optimization techniques to isolate the best possible drug candidates with a CMC model that enables quick and reliable production—aimed at delivering targeted treatment options to patients.

“At Paragon, we are thrilled to announce the launch of Apogee Therapeutics as our first independent company, and we are confident that the Apogee team is well positioned to execute and demonstrate therapeutic leadership in areas of high unmet need,” said K. Evan Thompson, Ph.D., Chief Operating Officer of Paragon. “The debut of Apogee validates our approach to advancing best-in-class biologics to patients through a range of opportunities, from new company creation and strategic partnerships to shaping programs in-house with our experienced and proven team.”